S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Biden To Unleash "Choke Point" Operation On America? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Biden To Unleash "Choke Point" Operation On America? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Biden To Unleash "Choke Point" Operation On America? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Biden To Unleash "Choke Point" Operation On America? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:DFFN

Diffusion Pharmaceuticals (DFFN) Stock Forecast, Price & News

$3.78
-0.04 (-1.05%)
(As of 06/2/2023 ET)
Compare
Today's Range
$3.74
$3.81
50-Day Range
$3.77
$5.16
52-Week Range
$3.55
$8.74
Volume
3,502 shs
Average Volume
8,030 shs
Market Capitalization
$7.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Diffusion Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
151.7% Upside
$9.50 Price Target
Short Interest
Healthy
0.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars


DFFN stock logo

About Diffusion Pharmaceuticals (NASDAQ:DFFN) Stock

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Receive DFFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DFFN Stock News Headlines

“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc. (DFFN)
DFFN: Phase 2 GBM Trial to Initiate 2H22…
See More Headlines

DFFN Price History

DFFN Company Calendar

Last Earnings
11/10/2021
Today
6/04/2023
Next Earnings (Estimated)
6/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DFFN
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$9.50
Low Stock Price Forecast
$9.50
Forecasted Upside/Downside
+151.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.98 per share

Miscellaneous

Free Float
2,003,000
Market Cap
$7.70 million
Optionable
Not Optionable
Beta
1.82

Key Executives

  • Robert J. Cobuzzi
    President, Chief Executive Officer & Director
  • William Hornung
    Chief Financial Officer
  • Kelly Arscott
    Director-Clinical Operations
  • Harry N. Cook
    Vice President-Clinical Operations
  • William R. Elder
    Secretary & General Counsel













DFFN Stock - Frequently Asked Questions

Should I buy or sell Diffusion Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DFFN shares.
View DFFN analyst ratings
or view top-rated stocks.

What is Diffusion Pharmaceuticals' stock price forecast for 2023?

1 Wall Street research analysts have issued twelve-month price objectives for Diffusion Pharmaceuticals' shares. Their DFFN share price forecasts range from $9.50 to $9.50. On average, they predict the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 151.7% from the stock's current price.
View analysts price targets for DFFN
or view top-rated stocks among Wall Street analysts.

How have DFFN shares performed in 2023?

Diffusion Pharmaceuticals' stock was trading at $5.0573 at the beginning of the year. Since then, DFFN shares have decreased by 25.4% and is now trading at $3.7750.
View the best growth stocks for 2023 here
.

Are investors shorting Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 9,700 shares, an increase of 148.7% from the April 30th total of 3,900 shares. Based on an average daily volume of 6,900 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.5% of the company's shares are sold short.
View Diffusion Pharmaceuticals' Short Interest
.

When is Diffusion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 8th 2023.
View our DFFN earnings forecast
.

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($6.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.00) by $4.00.

When did Diffusion Pharmaceuticals' stock split?

Diffusion Pharmaceuticals shares reverse split on the morning of Tuesday, April 19th 2022. The 1-50 reverse split was announced on Tuesday, April 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF).

What is Diffusion Pharmaceuticals' stock symbol?

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

How do I buy shares of Diffusion Pharmaceuticals?

Shares of DFFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Diffusion Pharmaceuticals' stock price today?

One share of DFFN stock can currently be purchased for approximately $3.78.

How much money does Diffusion Pharmaceuticals make?

Diffusion Pharmaceuticals (NASDAQ:DFFN) has a market capitalization of $7.70 million. The company earns $-15,590,000.00 in net income (profit) each year or ($7.65) on an earnings per share basis.

How can I contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The official website for the company is www.diffusionpharma.com. The company can be reached via phone at (434) 220-0718, via email at investorrealtions@diffusionpharma.com, or via fax at 434-220-0722.

This page (NASDAQ:DFFN) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -